載入中
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
一般交易時段
US$12.12
+US$0.01 · +0.08%
盤中時間採用ET。市場資料可能有所延遲。
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
日內區間
目前US$12.12
52週區間
目前US$12.12
盤中時間採用ET。市場資料可能有所延遲。
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
日內區間
目前US$12.12
52週區間
目前US$12.12
營業利益
淨利
| 項目（USD） | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | — | — | 457.5萬 USD |
| 毛利 | — | — | — | — | −457.5萬 USD |
| 研究與開發 | 2.21億 USD | 1.89億 USD | 1.75億 USD | 1.27億 USD | 8064.5萬 USD |
| 銷售、一般及管理費用 | 9873.5萬 USD | — | — | — | 3626.4萬 USD |
| 營業費用 | 3.2億 USD | 2.62億 USD | 2.35億 USD | 1.77億 USD | 1.17億 USD |
| 利息收入 | 1362.5萬 USD | 2112萬 USD | 2335.6萬 USD | 1000.6萬 USD | 39萬 USD |
| 利息支出 | 885.9萬 USD | 789.3萬 USD | 666萬 USD | 416萬 USD | 222.3萬 USD |
| 折舊和攤銷 | 333.2萬 USD | 350.2萬 USD | 265.5萬 USD | 244.7萬 USD | 214.7萬 USD |
| 營業利益 | −3.2億 USD | −2.62億 USD | −2.35億 USD | −1.77億 USD | −1.21億 USD |
| 淨利 | −3.14億 USD | −2.47億 USD | −2.16億 USD | −1.74億 USD | −1.18億 USD |
公司資料更新於 2026年10月14日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI3391.42萬0.33%102.75億 USD0.35%US$147.54+0.50%
Vanguard Morningstar Total Stock Market ETFVTI3018.21萬0.00%2.3兆 USD0.03%US$378.77-0.67%
iShares Russell 2000 ETFIWM2532.65萬0.03%777.48億 USD0.19%US$272.97-1.35%
Vanguard Extended Market ETFVXF1332.72萬0.01%954億 USD0.05%US$229.5-1.31%
iShares Biotechnology ETFIBB808.29萬0.08%107.38億 USD0.44%US$202.9+1.44%
Vanguard Russell 2000 ETFVTWO695.99萬0.04%180億 USD0.06%US$110.26-1.35%
F/M Emerald Life Sciences Innovation ETFLFSC535.74萬4.35%1.16億 USD0.79%US$41.205+0.63%
Schwab U.S. Small-Cap ETFSCHA513.35萬0.02%216.55億 USD0.03%US$32.145-1.27%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOF/M Emerald Life Sciences Innovation ETFLFSCSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
